Form 4: OptimizeRx CFO/COO Edward Stelmakh Reports Changes in Beneficial Ownership

Edward Stelmakh, CFO/COO of OptimizeRx Corp, reports the acquisition and disposal of common stock and grant of restricted stock units.

Summary

• On February 15, 2024, Edward Stelmakh, CFO/COO of OptimizeRx Corp, engaged in transactions involving the company's stock.
• He acquired 7,083 shares of common stock.
• He disposed of 14,765 shares of common stock.
• Following these transactions, Stelmakh directly owns 14,765 shares of OptimizeRx Corp.
• He also received a grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock, which will vest on February 15, 2025.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing changes in beneficial ownership. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The grant of restricted stock units to the CFO/COO aligns his interests with the long-term performance of the company.

Future Outlook

The restricted stock units will vest in full on February 15, 2025, which is the first anniversary of the date of grant.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the stock transactions of a key executive.

Key Dates